More Microscopic Brain Damage Seen in SPMS Than in RRMS

People with secondary progressive multiple sclerosis (SPMS) have more microscopic damage in normal-appearing brain tissue than do patients with relapsing-remitting multiple sclerosis (RRMS), according to a new imaging study. These patients also have a greater number of chronic active lesions than those with RRMS. “Using advanced diffusion MRI…

Calyx, Qynapse to Expand Use of Neuroimaging AI Tools

Calyx and Qynapse have joined forces to expand the use of artificial intelligence (AI)-based neuroimaging tools in clinical trials of treatment candidates for conditions affecting the central nervous system (CNS), or the brain and spinal cord. This is expected to help advance therapy development for multiple sclerosis…

Smoking Linked to Worse Outcomes in RRMS Patients After 10 Years

Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years, according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…

MS Research Prize Goes to Barcelona Neurologist

A researcher in Barcelona, Spain, has been chosen to receive the 2022 John Dystel Prize for his work advancing the understanding, diagnosis, and treatment of multiple sclerosis (MS). The $40,000 prize, given jointly by the National MS Society and the American Academy of Neurology (AAN), will be…

Qynapse Announces Research Collaborations for World MS Day

Qynapse, a company that combines artificial intelligence with neuroimaging technology, is reaffirming its commitment to help advance multiple sclerosis (MS) research and care in recognition of World MS Day. World MS Day is officially celebrated on May 30, with global events and activities designed to raise disease awareness.

Women in Family with MS Seen to Be at Particular Risk of Developing Disease

Family members of multiple sclerosis (MS) patients who are asymptomatic but at a higher risk of developing the disease themselves are more likely to have early signs of the disease, according to a study published in JAMA Neurology and titled "Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members". These people should therefore be closely monitored.